Key result
MYH9 N93K mutation enhances NM2-A filament stability and UNC45a interaction, driving distinct cytoplasmic aggregation.
Why the study?
Mutations in the MYH9 gene cause MYH9-related diseases, with motor domain mutations causing more severe phenotypes than dimerization/filamentation domain mutations through incompletely understood molecular mechanisms.
Distinct molecular defects caused by different MYH9 mutations affect the distribution and function of the wild type allele differently, potentially explaining the varying severity of MYH9-related diseases.
May warrant mutation-specific counseling in MYH9 disease; extends models of variable dominant-negative effects on wild-type myosin.
Mutations in the MYH9 gene, which encodes the heavy chain of the actin-based molecular motor non-muscle myosin II-A (NM2-A), cause a spectrum of rare blood disorders collectively termed MYH9-related diseases (MYH9-RD). Previous data indicate that mutations in the motor domain result in more severe phenotypes than those in the dimerization/filamentation domain. Here, we show that N93K mutation, previously described as motor-impairing, has only a minor effect on myosin motor function in vitro, but it significantly enhances NM2-A filament stability and interaction with the chaperone UNC45a. When expressed in stress fiber-competent cells, e.g., COS7 or U2OS, and stress fiber-incompetent cells, e.g., MEG-01, NM2-A N93K formed amorphous aggregates that colocalized with wild-type NM2-A, NM2-B and UNC45a, but not F-actin, tropomyosin-4 or phosphoSer19, active, RLC. Another motor mutant, NM2-A R705H, caused milder defects in filament stability, adhesion maturation and aggregation in both types of cells. Conversely, the tail domain mutant NM2-A E1841K enhanced filament stability in COS7 cells without forming aggregates, while it promoted the formation of small, elongated aggregates in MEG-01 cells that did not co-localize with wild type NM2-A. These data indicate that the molecular defect caused by NM2A-N93K affects the distribution and function of the wild type allele, whereas NM2-A E1841K aggregates do not affect the wild type allele, which could constitute the molecular basis of the differences in severity in mutant MYH9 allele carriers.
No takes yet. Share an insight, caveat, or question.
Llorente-González et al. (2026) studied Human cell lines (COS7, U2OS, MEG-01) expressing MYH9 mutations related to MYH9-related diseases, a spectrum of rare blood disorders with macrothrombocytopenia and various extra-hematological complications. Expression of MYH9 mutant NM2-A variants N93K, R705H, and E1841K vs. Wild type NM2-A expression was evaluated on NM2-A filament stability, cellular localization, aggregation phenotypes and interaction with chaperone UNC45a. MYH9 mutation N93K modestly reduces NM2-A motor activity but significantly enhances filament stability and interaction with UNC45a, causing distinct cytoplasmic aggregation with co-localization of wild-type NM2-A and NM2-B.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: